Juncell Therapeutics has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities acting as its exclusive sponsor. Juncell Therapeutics is a biotechnology company dedicated to developing innovative cell therapies and novel drugs for solid tumors, focusing on creating immune cell therapies that are safer, more effective, more accessible, and more affordable.

The company's core product, GC101, is the world's first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity lymphodepleting chemotherapy or IL-2 administration. It is expected to become the first TIL therapy approved for marketing in China. As a single-dose treatment, TIL cell therapy has the potential to deliver curative outcomes for certain patients with advanced tumors. Clinical data show that TIL therapy also provides long-term benefits to patients with various types of solid tumors, including advanced melanoma, non-small cell lung cancer (NSCLC), and breast cancer. In Phase I clinical trials for advanced metastatic solid tumors that have failed multiple lines of standard treatment, objective responses have been observed in melanoma, NSCLC, cervical cancer, and other solid tumors.

TIL therapy is a personalized treatment. Its core advantage lies in its breakthrough efficacy, while its drawbacks include complex manufacturing processes and intricate clinical protocols, leading to high overall costs and limited accessibility, which restricts its widespread adoption. To make this clinically valuable therapy accessible to a broader patient population, the company has implemented innovations from production to clinical application. While preserving the curative potential of TIL therapy, these innovations simplify both the manufacturing process and clinical protocols, significantly enhancing the safety, accessibility, and affordability of TIL cell therapy.

In recent years, the global oncology drug market has experienced robust growth. In 2024, the market size reached USD 253.3 billion, with a compound annual growth rate (CAGR) of 13.9% from 2020 to 2024. It is projected to expand further to USD 452.5 billion by 2030, with a CAGR of 10.2% from 2024 to 2030, and reach USD 702.7 billion by 2035, with a CAGR of 9.2% from 2030 to 2035. In China, the oncology drug market size reached RMB 258.2 billion in 2024, with a CAGR of 6.9% from 2020 to 2024. The market is expected to accelerate in the coming years, growing to RMB 527.3 billion by 2030.

Reference：https://finance.eastmoney.com/a/202512113588278753.html